Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Akorn

This page shows the latest Akorn news and features for those working in and with pharma, biotech and healthcare.

Data integrity scuppers Fresenius deal with Akorn

Data integrity scuppers Fresenius deal with Akorn

Akorn is furious about the decision, and says it intends to hold Fresenius to its obligations under the merger agreement. ... Akorn can claim a termination fee, which in the original merger agreement was valued at $129m.

Latest news

  • Fresenius says Akorn investigation could affect takeover Fresenius says Akorn investigation could affect takeover

    The company says it is conducting an independent investigation - using external experts - into “alleged breaches of FDA data integrity requirements relating to product development at Akorn”. ... Sales for Akorn’s small consumer health business

  • Fresenius Kabi buys Akorn and Merck's biosimilar businesses Fresenius Kabi buys Akorn and Merck's biosimilar businesses

    Fresenius is paying $34 per share for Akorn - valuing the company at $4.3bn - and will also assume around $450m in debt held by the US firm. ... Rumours of a deal have been circulating for several weeks, and Akorn confirmed it was in negotiations with

  • Survival strategy

    A recent example of Big Pharma's entry into the generic marketplace was the purchase by Pfizer in December of 22 abbreviated new drug applications for $56m from the Akorn-Strides ... 80. Akorn-Strides/Pfizer. Acquisition of 22 ANDAs in US. Registration.

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch - May 2017 Deal Watch - May 2017

    is making two acquisitions worth over $5.5bn.  The acquisition of Akorn, a US based company that manufactures “alternate” formulations such as liquids, gels and injectables  and markets a range of ... 6, 100. Akorn (US). Fresenius (DE). Company

  • Pharma deals during September 2014 Pharma deals during September 2014

    The contract manufacturing sector is in a state of flux with the acquisition of Patheon last year by DSM and Akorn's acquisition of the ophthalmic manufacturer Excelvision in July this

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    45. ECR Pharmaceuticals / Valeant. Company acquisition. Akorn subsidiary with branded generics business.

  • Deal Watch table for May 2014 Deal Watch table for May 2014

    VersaPharm / Akorn. Company acquisition. US generic company selling dermatology products with $100m sales.

  • Pharma deals during May 2014 Pharma deals during May 2014

    Merck sold its US ophthalmic business in 2013 for 1.5 x sales to Akorn. ... Akorn acquired Versapharm, a privately-owned US company that develops and markets generic dermatology products.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Quick links

Infographics

Multimedia